Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Key Takeaways More U.S. teens are getting weight-loss surgeryThe procedures increased 15% between 2021 and 2023At the same ...

The analysis of 11 weight-loss drug studies by the University of Oxford found that patients typically lost 8kg (18lb) after ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

President Donald Trump told Fox News host Sean Hannity that the pal who starred in the "fat shot" story was "very worried" ...